The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Martina Bocchetta; Samantha Galluzzi; Patrick Gavin Kehoe; Eduardo Aguera; Roberto Bernabei; Roger Bullock; Mathieu Ceccaldi; Jean-François Dartigues; Alexandre de Mendonça; Mira Didic; Maria Eriksdotter; Olivier Félician; Lutz Frölich; Hermann-Josef Gertz; Merja Hallikainen; Steen G Hasselbalch; Lucrezia Hausner; Isabell Heuser; Frank Jessen; Roy W Jones; Alexander Kurz; Brian Lawlor; Alberto Lleo; Pablo Martinez-Lage; Patrizia Mecocci; Shima Mehrabian; Andreas Monsch; Flavio Nobili; Agneta Nordberg; Marcel Olde Rikkert; Jean-Marc Orgogozo; Florence Pasquier; Oliver Peters; Eric Salmon; Carmen Sánchez-Castellano; Isabel Santana; Marie Sarazin; Latchezar Traykov; Magda Tsolaki; Pieter Jelle Visser; Åsa K Wallin; Gordon Wilcock; David Wilkinson; Henrike Wolf; Görsev Yener; Dina Zekry; Giovanni B Frisoni

doi:10.1016/j.jalz.2014.06.006

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Martina Bocchetta, Samantha Galluzzi, Patrick Gavin Kehoe, Eduardo Aguera, Roberto Bernabei, Roger Bullock, Mathieu Ceccaldi, Jean-François Dartigues, Alexandre de Mendonça, Mira Didic, Maria Eriksdotter, Olivier Félician, Lutz Frölich, Hermann-Josef Gertz, Merja Hallikainen, Steen G Hasselbalch, Lucrezia Hausner, Isabell Heuser, Frank Jessen, Roy W JonesAlexander Kurz, Brian Lawlor, Alberto Lleo, Pablo Martinez-Lage, Patrizia Mecocci, Shima Mehrabian, Andreas Monsch, Flavio Nobili, Agneta Nordberg, Marcel Olde Rikkert, Jean-Marc Orgogozo, Florence Pasquier, Oliver Peters, Eric Salmon, Carmen Sánchez-Castellano, Isabel Santana, Marie Sarazin, Latchezar Traykov, Magda Tsolaki, Pieter Jelle Visser, Åsa K Wallin, Gordon Wilcock, David Wilkinson, Henrike Wolf, Görsev Yener, Dina Zekry, Giovanni B Frisoni

Institut for Klinisk Medicin

46 Citationer (Scopus)

Abstract

We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI).We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Ab42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/ frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P ,.02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.

Originalsprog	Engelsk
Tidsskrift	Alzheimer's & Dementia
Vol/bind	11
Udgave nummer	2
Sider (fra-til)	195-206.e1
Antal sider	13
ISSN	1552-5260
DOI	https://doi.org/10.1016/j.jalz.2014.06.006
Status	Udgivet - feb. 2015

Adgang til dokumentet

10.1016/j.jalz.2014.06.006

Citationsformater

Bocchetta, M., Galluzzi, S., Kehoe, P. G., Aguera, E., Bernabei, R., Bullock, R., Ceccaldi, M., Dartigues, J.-F., de Mendonça, A., Didic, M., Eriksdotter, M., Félician, O., Frölich, L., Gertz, H.-J., Hallikainen, M., Hasselbalch, S. G., Hausner, L., Heuser, I., Jessen, F., ... Frisoni, G. B. (2015). The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's & Dementia, 11(2), 195-206.e1. https://doi.org/10.1016/j.jalz.2014.06.006

Bocchetta, M, Galluzzi, S, Kehoe, PG, Aguera, E, Bernabei, R, Bullock, R, Ceccaldi, M, Dartigues, J-F, de Mendonça, A, Didic, M, Eriksdotter, M, Félician, O, Frölich, L, Gertz, H-J, Hallikainen, M, Hasselbalch, SG, Hausner, L, Heuser, I, Jessen, F, Jones, RW, Kurz, A, Lawlor, B, Lleo, A, Martinez-Lage, P, Mecocci, P, Mehrabian, S, Monsch, A, Nobili, F, Nordberg, A, Rikkert, MO, Orgogozo, J-M, Pasquier, F, Peters, O, Salmon, E, Sánchez-Castellano, C, Santana, I, Sarazin, M, Traykov, L, Tsolaki, M, Visser, PJ, Wallin, ÅK, Wilcock, G, Wilkinson, D, Wolf, H, Yener, G, Zekry, D & Frisoni, GB 2015, 'The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey', Alzheimer's & Dementia, bind 11, nr. 2, s. 195-206.e1. https://doi.org/10.1016/j.jalz.2014.06.006

@article{ff9a925bfc8d490d86605f363c6d67b9,

title = "The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey",

abstract = "We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI).We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Ab42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it {"}always/ frequently{"}) followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as {"}moderate{"}. Seventy-nine percent of responders felt {"}very/extremely{"} comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P ,.02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.",

keywords = "Alzheimer Disease, Amyloid beta-Peptides, Atrophy, Biomarkers, Brain, Europe, Fluorodeoxyglucose F18, Internet, Magnetic Resonance Imaging, Mild Cognitive Impairment, Peptide Fragments, Positron-Emission Tomography, Practice Patterns, Physicians', Radiopharmaceuticals, Surveys and Questionnaires, tau Proteins",

author = "Martina Bocchetta and Samantha Galluzzi and Kehoe, {Patrick Gavin} and Eduardo Aguera and Roberto Bernabei and Roger Bullock and Mathieu Ceccaldi and Jean-Fran{\c c}ois Dartigues and {de Mendon{\c c}a}, Alexandre and Mira Didic and Maria Eriksdotter and Olivier F{\'e}lician and Lutz Fr{\"o}lich and Hermann-Josef Gertz and Merja Hallikainen and Hasselbalch, {Steen G} and Lucrezia Hausner and Isabell Heuser and Frank Jessen and Jones, {Roy W} and Alexander Kurz and Brian Lawlor and Alberto Lleo and Pablo Martinez-Lage and Patrizia Mecocci and Shima Mehrabian and Andreas Monsch and Flavio Nobili and Agneta Nordberg and Rikkert, {Marcel Olde} and Jean-Marc Orgogozo and Florence Pasquier and Oliver Peters and Eric Salmon and Carmen S{\'a}nchez-Castellano and Isabel Santana and Marie Sarazin and Latchezar Traykov and Magda Tsolaki and Visser, {Pieter Jelle} and Wallin, {{\AA}sa K} and Gordon Wilcock and David Wilkinson and Henrike Wolf and G{\"o}rsev Yener and Dina Zekry and Frisoni, {Giovanni B}",

year = "2015",

month = feb,

doi = "10.1016/j.jalz.2014.06.006",

language = "English",

volume = "11",

pages = "195--206.e1",

journal = "Alzheimer's & Dementia",

issn = "1552-5260",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - The use of biomarkers for the etiologic diagnosis of MCI in Europe

T2 - An EADC survey

AU - Bocchetta, Martina

AU - Galluzzi, Samantha

AU - Kehoe, Patrick Gavin

AU - Aguera, Eduardo

AU - Bernabei, Roberto

AU - Bullock, Roger

AU - Ceccaldi, Mathieu

AU - Dartigues, Jean-François

AU - de Mendonça, Alexandre

AU - Didic, Mira

AU - Eriksdotter, Maria

AU - Félician, Olivier

AU - Frölich, Lutz

AU - Gertz, Hermann-Josef

AU - Hallikainen, Merja

AU - Hasselbalch, Steen G

AU - Hausner, Lucrezia

AU - Heuser, Isabell

AU - Jessen, Frank

AU - Jones, Roy W

AU - Kurz, Alexander

AU - Lawlor, Brian

AU - Lleo, Alberto

AU - Martinez-Lage, Pablo

AU - Mecocci, Patrizia

AU - Mehrabian, Shima

AU - Monsch, Andreas

AU - Nobili, Flavio

AU - Nordberg, Agneta

AU - Rikkert, Marcel Olde

AU - Orgogozo, Jean-Marc

AU - Pasquier, Florence

AU - Peters, Oliver

AU - Salmon, Eric

AU - Sánchez-Castellano, Carmen

AU - Santana, Isabel

AU - Sarazin, Marie

AU - Traykov, Latchezar

AU - Tsolaki, Magda

AU - Visser, Pieter Jelle

AU - Wallin, Åsa K

AU - Wilcock, Gordon

AU - Wilkinson, David

AU - Wolf, Henrike

AU - Yener, Görsev

AU - Zekry, Dina

AU - Frisoni, Giovanni B

PY - 2015/2

Y1 - 2015/2

N2 - We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI).We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Ab42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/ frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P ,.02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.

AB - We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI).We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Ab42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/ frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P ,.02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.

KW - Alzheimer Disease

KW - Amyloid beta-Peptides

KW - Atrophy

KW - Biomarkers

KW - Brain

KW - Europe

KW - Fluorodeoxyglucose F18

KW - Internet

KW - Magnetic Resonance Imaging

KW - Mild Cognitive Impairment

KW - Peptide Fragments

KW - Positron-Emission Tomography

KW - Practice Patterns, Physicians'

KW - Radiopharmaceuticals

KW - Surveys and Questionnaires

KW - tau Proteins

U2 - 10.1016/j.jalz.2014.06.006

DO - 10.1016/j.jalz.2014.06.006

M3 - Journal article

C2 - 25150733

SN - 1552-5260

VL - 11

SP - 195-206.e1

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

IS - 2

ER -

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater